- Home
- ALT vs TTGT Comparison
ALT vs TTGT Comparison
Compare ALT & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | TTGT |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 373.1M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ALT | TTGT |
|---|---|---|
| Price | $4.54 | $5.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $16.00 | $11.25 |
| AVG Volume (30 Days) | ★ 6.0M | 346.2K |
| Earning Date | 02-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $20,000.00 | ★ $446,514,000.00 |
| Revenue This Year | N/A | $74.33 |
| Revenue Next Year | N/A | $3.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 71.55 |
| 52 Week Low | $2.90 | $4.63 |
| 52 Week High | $7.73 | $19.29 |
Technical Indicators
Market Signals| Indicator | ALT | TTGT |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 50.52 |
| Support Level | $4.03 | $5.02 |
| Resistance Level | $4.40 | $5.59 |
| Average True Range (ATR) | 0.26 | 0.28 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 99.56 | 59.38 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.